[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Special Article
November 1998

Clinical Research Designs for Emerging Treatments for Alzheimer DiseaseMoving Beyond Placebo-Controlled Trials

Author Affiliations

From the Department of Neurology (Dr Knopman) and the Center for Bioethics (Drs Kahn and Miles), University of Minnesota, Minneapolis. Dr Knopman has served as a paid consultant to Parke-Davis Pharmaceutical Research Division, Ann Arbor, Mich; Athena Neurosciences Inc, South San Francisco, Calif; Bayer Corp, West Haven, Conn; Eisai/Pfizer Inc, New York, NY; Novartis Pharmaceuticals Corp, East Hanover, NJ; and Wyeth-Ayerst Laboratories, Philadelphia, Pa. He is currently conducting clinical trials with Bayer, Sigma-Tau Pharmaceuticals Inc, Gaithersburg, Md, and Forest Pharmaceuticals Inc, Maryland Heights, Mo. Drs Kahn and Miles have had no contacts with the pharmaceutical industry with regard to Alzheimer disease therapies.

Arch Neurol. 1998;55(11):1425-1429. doi:10.1001/archneur.55.11.1425
Abstract

The design of clinical trials must evolve as new therapies become available. The demonstrated efficacy and clinical use of donepezil and vitamin E for Alzheimer disease (AD) has shifted the options for AD research design. There is now a compelling case for alternatives to trials that include a treatment arm with no active therapy (ie, a placebo control). With an existing therapy, such as donepezil or vitamin E, new drugs that are clearly superior to those drugs should be sought. Combination therapy is a likely strategy for the future, implying that clinical trials, if possible, should replicate actual practice. The long duration of future AD trials also will make placebo-controlled trials more difficult to justify and more difficult to recruit for. Add-on or active-control designs represent the alternative approaches. We believe that definitive clinical trials of new AD drugs that use one or the other of these designs would be more likely to bring about therapeutic advances than would comparisons with inactive treatments. Our argument is not a general rejection of placebo-control designs. Our recommendations apply only to the circumstances in which the field of AD drug therapy now finds itself.

×